Global Nonalcoholic Steatohepatitis Treatment Market
Global Nonalcoholic Steatohepatitis Treatment Market

Nonalcoholic Steatohepatitis Treatment Comprehensive Study by Distribution (Hospital Pharmacy, Online Provider, Retail Pharmacy), Medication (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc), End User (Pediatric, Adult, Geriatric) Players and Region - Global Market Outlook to 2026

Nonalcoholic Steatohepatitis Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Sep 2021 Edition 222 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Nonalcoholic Steatohepatitis Treatment Market Scope
Non-alcoholic fatty liver disease, defined as the development of macrovascular steatosis in the presence of less than 20 grammes of alcohol intake per day, is the most prevalent liver disease in the Western world. It is most often related with insulin resistance/type 2 diabetes mellitus and obesity. It manifests as steatosis, steatohepatitis, cirrhosis, and, in rare cases, hepatocellular cancer. Hepatic steatosis is caused by an imbalance between fat absorption, oxidation, and export. Insulin resistance, which predisposes to lipolysis of peripheral fat and mobilisation and absorption of fatty acids by the liver, is the most constant underlying pathogenic cause. The growing clinical and economic burden of NAFLD has emphasised the need for a more simplified approach to disease prevention, diagnosis, and treatment.

The Nonalcoholic Steatohepatitis Treatment market study is segmented and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Nonalcoholic Steatohepatitis Treatment market throughout the predicted period.

Allergan plc. (United States), Cadila Healthcare Limited (India), Conatus Pharmaceuticals Inc. (United States), Galmed Pharmaceuticals Ltd (Israel), Gemphire Therapeutics Inc. (United States), Genfit SA (France), Gilead Sciences, Inc. (United States), Intercept Pharmaceuticals, Inc. (United States), Novartis International AG (Switzerland) and Shire Plc. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Nonalcoholic Steatohepatitis Treatment market by Type, Application and Region.

On the basis of geography, the market of Nonalcoholic Steatohepatitis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 5th March 2020 - Zydus Cadila Launched Drug for NASH. The Launched Was Followed by Drug Controller General of India (DCGI) Approval to Zydus’s “Saroglitazar” for Treatment of Non-Cirrhotic, Non-Alcoholic Steatohepatitis (NASH) In India, Making It the First-Ever Drug for Treatment of The Disease.


Market Trend
  • Rising Geriatric Population

Market Drivers
  • Prevalence of Nonalcoholic Steatohepatitis Cases
  • High Investment in Pharmaceutical R&D

Opportunities
  • Growing Healthcare Infrastructure Across Emerging Regions

Restraints
  • Lack of Skilled Professionals
  • Side Effects and Adverse Reactions

Challenges
  • Fierce Competitive Pressure


Key Target Audience
Nonalcoholic Steatohepatitis Treatment Providers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Nonalcoholic Steatohepatitis Treatment Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Distribution
  • Hospital Pharmacy
  • Online Provider
  • Retail Pharmacy

By Medication
  • Vitamin E & Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib & Cenicriviroc

By End User
  • Pediatric
  • Adult
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Nonalcoholic Steatohepatitis Cases
      • 3.2.2. High Investment in Pharmaceutical R&D
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. Rising Geriatric Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nonalcoholic Steatohepatitis Treatment, by Distribution, Medication, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Nonalcoholic Steatohepatitis Treatment (Value)
      • 5.2.1. Global Nonalcoholic Steatohepatitis Treatment by: Distribution (Value)
        • 5.2.1.1. Hospital Pharmacy
        • 5.2.1.2. Online Provider
        • 5.2.1.3. Retail Pharmacy
      • 5.2.2. Global Nonalcoholic Steatohepatitis Treatment by: Medication (Value)
        • 5.2.2.1. Vitamin E & Pioglitazone
        • 5.2.2.2. Ocaliva
        • 5.2.2.3. Elafibranor
        • 5.2.2.4. Selonsertib & Cenicriviroc
      • 5.2.3. Global Nonalcoholic Steatohepatitis Treatment by: End User (Value)
        • 5.2.3.1. Pediatric
        • 5.2.3.2. Adult
        • 5.2.3.3. Geriatric
      • 5.2.4. Global Nonalcoholic Steatohepatitis Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Nonalcoholic Steatohepatitis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan plc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cadila Healthcare Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Conatus Pharmaceuticals Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Galmed Pharmaceuticals Ltd (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Gemphire Therapeutics Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genfit SA (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Gilead Sciences, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Intercept Pharmaceuticals, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Shire Plc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Nonalcoholic Steatohepatitis Treatment Sale, by Distribution, Medication, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Nonalcoholic Steatohepatitis Treatment (Value)
      • 7.2.1. Global Nonalcoholic Steatohepatitis Treatment by: Distribution (Value)
        • 7.2.1.1. Hospital Pharmacy
        • 7.2.1.2. Online Provider
        • 7.2.1.3. Retail Pharmacy
      • 7.2.2. Global Nonalcoholic Steatohepatitis Treatment by: Medication (Value)
        • 7.2.2.1. Vitamin E & Pioglitazone
        • 7.2.2.2. Ocaliva
        • 7.2.2.3. Elafibranor
        • 7.2.2.4. Selonsertib & Cenicriviroc
      • 7.2.3. Global Nonalcoholic Steatohepatitis Treatment by: End User (Value)
        • 7.2.3.1. Pediatric
        • 7.2.3.2. Adult
        • 7.2.3.3. Geriatric
      • 7.2.4. Global Nonalcoholic Steatohepatitis Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nonalcoholic Steatohepatitis Treatment: by Distribution(USD Million)
  • Table 2. Nonalcoholic Steatohepatitis Treatment Hospital Pharmacy , by Region USD Million (2015-2020)
  • Table 3. Nonalcoholic Steatohepatitis Treatment Online Provider , by Region USD Million (2015-2020)
  • Table 4. Nonalcoholic Steatohepatitis Treatment Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 5. Nonalcoholic Steatohepatitis Treatment: by Medication(USD Million)
  • Table 6. Nonalcoholic Steatohepatitis Treatment Vitamin E & Pioglitazone , by Region USD Million (2015-2020)
  • Table 7. Nonalcoholic Steatohepatitis Treatment Ocaliva , by Region USD Million (2015-2020)
  • Table 8. Nonalcoholic Steatohepatitis Treatment Elafibranor , by Region USD Million (2015-2020)
  • Table 9. Nonalcoholic Steatohepatitis Treatment Selonsertib & Cenicriviroc , by Region USD Million (2015-2020)
  • Table 10. Nonalcoholic Steatohepatitis Treatment: by End User(USD Million)
  • Table 11. Nonalcoholic Steatohepatitis Treatment Pediatric , by Region USD Million (2015-2020)
  • Table 12. Nonalcoholic Steatohepatitis Treatment Adult , by Region USD Million (2015-2020)
  • Table 13. Nonalcoholic Steatohepatitis Treatment Geriatric , by Region USD Million (2015-2020)
  • Table 14. South America Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2015-2020)
  • Table 15. South America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 16. South America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 17. South America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 18. Brazil Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 19. Brazil Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 20. Brazil Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 21. Argentina Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 22. Argentina Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 23. Argentina Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 24. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 25. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 26. Rest of South America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 27. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 29. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 30. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 31. China Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 32. China Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 33. China Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 34. Japan Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 35. Japan Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 36. Japan Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 37. India Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 38. India Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 39. India Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 40. South Korea Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 41. South Korea Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 42. South Korea Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 43. Taiwan Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 44. Taiwan Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 45. Taiwan Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 46. Australia Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 47. Australia Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 48. Australia Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 52. Europe Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2015-2020)
  • Table 53. Europe Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 54. Europe Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 55. Europe Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 56. Germany Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 57. Germany Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 58. Germany Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 59. France Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 60. France Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 61. France Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 62. Italy Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 63. Italy Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 64. Italy Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 65. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 66. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 67. United Kingdom Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 68. Netherlands Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 69. Netherlands Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 70. Netherlands Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 71. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 72. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 73. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 74. MEA Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2015-2020)
  • Table 75. MEA Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 76. MEA Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 77. MEA Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 78. Middle East Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 79. Middle East Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 80. Middle East Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 81. Africa Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 82. Africa Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 83. Africa Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 84. North America Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2015-2020)
  • Table 85. North America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 86. North America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 87. North America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 88. United States Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 89. United States Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 90. United States Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 91. Canada Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 92. Canada Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 93. Canada Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 94. Mexico Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2015-2020)
  • Table 95. Mexico Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2015-2020)
  • Table 96. Mexico Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Nonalcoholic Steatohepatitis Treatment: by Distribution(USD Million)
  • Table 108. Nonalcoholic Steatohepatitis Treatment Hospital Pharmacy , by Region USD Million (2021-2026)
  • Table 109. Nonalcoholic Steatohepatitis Treatment Online Provider , by Region USD Million (2021-2026)
  • Table 110. Nonalcoholic Steatohepatitis Treatment Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 111. Nonalcoholic Steatohepatitis Treatment: by Medication(USD Million)
  • Table 112. Nonalcoholic Steatohepatitis Treatment Vitamin E & Pioglitazone , by Region USD Million (2021-2026)
  • Table 113. Nonalcoholic Steatohepatitis Treatment Ocaliva , by Region USD Million (2021-2026)
  • Table 114. Nonalcoholic Steatohepatitis Treatment Elafibranor , by Region USD Million (2021-2026)
  • Table 115. Nonalcoholic Steatohepatitis Treatment Selonsertib & Cenicriviroc , by Region USD Million (2021-2026)
  • Table 116. Nonalcoholic Steatohepatitis Treatment: by End User(USD Million)
  • Table 117. Nonalcoholic Steatohepatitis Treatment Pediatric , by Region USD Million (2021-2026)
  • Table 118. Nonalcoholic Steatohepatitis Treatment Adult , by Region USD Million (2021-2026)
  • Table 119. Nonalcoholic Steatohepatitis Treatment Geriatric , by Region USD Million (2021-2026)
  • Table 120. South America Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2021-2026)
  • Table 121. South America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 122. South America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 123. South America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 124. Brazil Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 125. Brazil Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 126. Brazil Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 127. Argentina Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 128. Argentina Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 129. Argentina Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 130. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 131. Rest of South America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 132. Rest of South America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 133. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2021-2026)
  • Table 134. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 135. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 136. Asia Pacific Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 137. China Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 138. China Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 139. China Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 140. Japan Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 141. Japan Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 142. Japan Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 143. India Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 144. India Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 145. India Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 146. South Korea Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 147. South Korea Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 148. South Korea Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 149. Taiwan Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 150. Taiwan Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 151. Taiwan Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 152. Australia Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 153. Australia Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 154. Australia Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 158. Europe Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2021-2026)
  • Table 159. Europe Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 160. Europe Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 161. Europe Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 162. Germany Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 163. Germany Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 164. Germany Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 165. France Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 166. France Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 167. France Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 168. Italy Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 169. Italy Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 170. Italy Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 171. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 172. United Kingdom Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 173. United Kingdom Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 174. Netherlands Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 175. Netherlands Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 176. Netherlands Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 177. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 178. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 179. Rest of Europe Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 180. MEA Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2021-2026)
  • Table 181. MEA Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 182. MEA Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 183. MEA Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 184. Middle East Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 185. Middle East Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 186. Middle East Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 187. Africa Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 188. Africa Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 189. Africa Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 190. North America Nonalcoholic Steatohepatitis Treatment, by Country USD Million (2021-2026)
  • Table 191. North America Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 192. North America Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 193. North America Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 194. United States Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 195. United States Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 196. United States Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 197. Canada Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 198. Canada Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 199. Canada Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 200. Mexico Nonalcoholic Steatohepatitis Treatment, by Distribution USD Million (2021-2026)
  • Table 201. Mexico Nonalcoholic Steatohepatitis Treatment, by Medication USD Million (2021-2026)
  • Table 202. Mexico Nonalcoholic Steatohepatitis Treatment, by End User USD Million (2021-2026)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nonalcoholic Steatohepatitis Treatment: by Distribution USD Million (2015-2020)
  • Figure 5. Global Nonalcoholic Steatohepatitis Treatment: by Medication USD Million (2015-2020)
  • Figure 6. Global Nonalcoholic Steatohepatitis Treatment: by End User USD Million (2015-2020)
  • Figure 7. South America Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 8. Asia Pacific Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 9. Europe Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 10. MEA Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 11. North America Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 12. Global Nonalcoholic Steatohepatitis Treatment share by Players 2020 (%)
  • Figure 13. Global Nonalcoholic Steatohepatitis Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Nonalcoholic Steatohepatitis Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allergan plc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Allergan plc. (United States) Revenue: by Geography 2020
  • Figure 18. Cadila Healthcare Limited (India) Revenue, Net Income and Gross profit
  • Figure 19. Cadila Healthcare Limited (India) Revenue: by Geography 2020
  • Figure 20. Conatus Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Conatus Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Galmed Pharmaceuticals Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 23. Galmed Pharmaceuticals Ltd (Israel) Revenue: by Geography 2020
  • Figure 24. Gemphire Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Gemphire Therapeutics Inc. (United States) Revenue: by Geography 2020
  • Figure 26. Genfit SA (France) Revenue, Net Income and Gross profit
  • Figure 27. Genfit SA (France) Revenue: by Geography 2020
  • Figure 28. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Gilead Sciences, Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Intercept Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Intercept Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 34. Shire Plc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Shire Plc. (United States) Revenue: by Geography 2020
  • Figure 36. Global Nonalcoholic Steatohepatitis Treatment: by Distribution USD Million (2021-2026)
  • Figure 37. Global Nonalcoholic Steatohepatitis Treatment: by Medication USD Million (2021-2026)
  • Figure 38. Global Nonalcoholic Steatohepatitis Treatment: by End User USD Million (2021-2026)
  • Figure 39. South America Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 40. Asia Pacific Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 41. Europe Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 42. MEA Nonalcoholic Steatohepatitis Treatment Share (%), by Country
  • Figure 43. North America Nonalcoholic Steatohepatitis Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Allergan plc. (United States)
  • Cadila Healthcare Limited (India)
  • Conatus Pharmaceuticals Inc. (United States)
  • Galmed Pharmaceuticals Ltd (Israel)
  • Gemphire Therapeutics Inc. (United States)
  • Genfit SA (France)
  • Gilead Sciences, Inc. (United States)
  • Intercept Pharmaceuticals, Inc. (United States)
  • Novartis International AG (Switzerland)
  • Shire Plc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation